A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

by Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan, Craig L. Slingluff
Published 2019-06-01

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

by Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall, Craig L. Slingluff
Published 2017-11-01

Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

by David J DeGraff, Peter E Clark, Justin M Cates, Hironobu Yamashita, Victoria L Robinson, Xiuping Yu, Mark E Smolkin, Sam S Chang, Michael S Cookson, Mary K Herrick, Shahrokh F Shariat, Gary D Steinberg, Henry F Frierson, Xue-Ru Wu, Dan Theodorescu, Robert J Matusik
Published 2012-01-01

IgG Subclass Determines Suppression Versus Enhancement of Humoral Alloimmunity to Kell RBC Antigens in Mice

by Paurvi Shinde, Heather L. Howie, Tamara C. Stegmann, Ariel M. Hay, Hayley R. Waterman, Zoltan Szittner, Arthur E. H. Bentlage, Linda Kapp, Suzanne N. Lissenberg-Thunnissen, Gillian Dekkers, Richard B. M. Schasfoort, Sarah J. Ratcliffe, Mark E. Smolkin, Gestur Vidarsson, C. Ellen van der Schoot, Krystalyn E. Hudson, James C. Zimring, James C. Zimring
Published 2020-07-01